ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis

Ann Surg Oncol. 2020 Oct;27(10):3961-3962. doi: 10.1245/s10434-020-08542-2. Epub 2020 May 5.

Authors

Hao Liu¹, Amer Zureikat²

Affiliations

¹ Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA.
² Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA. [email protected].

PMID: 32372314
DOI: 10.1245/s10434-020-08542-2

No abstract available

MeSH terms

CA-19-9 Antigen*
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / mortality
Survival Rate

Substances

CA-19-9 Antigen